Literature DB >> 24081340

Counterpoint: Should antipyretic therapy be given routinely to febrile patients in septic shock? No.

Anne M Drewry1, Richard S Hotchkiss2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24081340      PMCID： PMC3787912          DOI： 10.1378/chest.13-0918

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  19 in total

1.  The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study.

Authors:  Carl I Schulman; Nicholas Namias; James Doherty; Ronald J Manning; Pamela Li; Pam Li; Ahmed Elhaddad; Ahmed Alhaddad; David Lasko; Jose Amortegui; Christopher J Dy; Lucie Dlugasch; Gio Baracco; Stephen M Cohn
Journal:  Surg Infect (Larchmt)       Date:  2005       Impact factor: 2.150

Review 2.  External cooling in the management of fever.

Authors:  P Axelrod
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

3.  The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

Authors:  G R Bernard; A P Wheeler; J A Russell; R Schein; W R Summer; K P Steinberg; W J Fulkerson; P E Wright; B W Christman; W D Dupont; S B Higgins; B B Swindell
Journal:  N Engl J Med       Date:  1997-03-27       Impact factor: 91.245

4.  Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.

Authors:  Valerio Gozzoli; Miriam M Treggiari; Gian-Reto Kleger; Pascale Roux-Lombard; Marc Fathi; Claude Pichard; Jacques-André Romand
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

5.  Adverse effects of febrile state on cardiac performance.

Authors:  M T Haupt; E C Rackow
Journal:  Am Heart J       Date:  1983-05       Impact factor: 4.749

6.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).

Authors:  Olivier Leroy; Jean-Pierre Gangneux; Philippe Montravers; Jean-Paul Mira; François Gouin; Jean-Pierre Sollet; Jean Carlet; Jacques Reynes; Michel Rosenheim; Bernard Regnier; Olivier Lortholary
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

7.  Occurrence and outcome of fever in critically ill adults.

Authors:  Kevin B Laupland; Reza Shahpori; Andrew W Kirkpatrick; Terry Ross; Daniel B Gregson; H Thomas Stelfox
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

8.  Effect of cooling on oxygen consumption in febrile critically ill patients.

Authors:  C A Manthous; J B Hall; D Olson; M Singh; W Chatila; A Pohlman; R Kushner; G A Schmidt; L D Wood
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

9.  Body temperature alterations in the critically ill.

Authors:  Daliana Peres Bota; Flavio Lopes Ferreira; Christian Mélot; Jean Louis Vincent
Journal:  Intensive Care Med       Date:  2004-02-04       Impact factor: 17.440

10.  A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.

Authors:  Peter E Morris; John T Promes; Kalpalatha K Guntupalli; Patrick E Wright; Murray M Arons
Journal:  Crit Care       Date:  2010-06-30       Impact factor: 9.097
View more
  3 in total

1.  Antipyretic therapy in critically ill patients with sepsis: an interaction with body temperature.

Authors:  Zhongheng Zhang; Lin Chen; Hongying Ni
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

2.  Antipyretic therapy in critically ill patients with established sepsis: a trial sequential analysis.

Authors:  Zhongheng Zhang
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

3.  Core warming of coronavirus disease 2019 (COVID-19) patients undergoing mechanical ventilation-A protocol for a randomized controlled pilot study.

Authors:  Nathaniel Bonfanti; Emily Gundert; Anne M Drewry; Kristina Goff; Roger Bedimo; Erik Kulstad
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.